Pharmacokinetics, disposition, and biotransformation of the cardiac myosin inhibitor aficamten in humans
Abstract Aficamten, a cardiac myosin inhibitor, is being developed for the treatment of patients with symptomatic hypertrophic cardiomyopathy (HCM). The purpose of this study was to determine the absorption, metabolism, and excretion of aficamten. Eight healthy male participants received a single or...
Salvato in:
| Autori principali: | , , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Wiley
2024-10-01
|
| Serie: | Pharmacology Research & Perspectives |
| Soggetti: | |
| Accesso online: | https://doi.org/10.1002/prp2.70006 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|